Overview

• The MHRA’s Yellow Card scheme has logged nearly 400 suspected cases of acute pancreatitis and other pancreatic inflammation linked to GLP-1 therapies.
• At least ten of the reported pancreatic events have resulted in death, highlighting the potential severity of this side effect.
• The regulator has opened a formal investigation and plans genomic screening to identify patients with heightened susceptibility to pancreatitis.
• U.S. health authorities continue to mandate pancreatitis warnings on all GLP-1 drug labels but have not initiated a formal inquiry.
• Manufacturers Lilly and Novo Nordisk stress ongoing safety surveillance, a positive benefit-risk assessment, and recommend use only under medical supervision.